ArticleApplied microbiology and biotechnology2026
Biotransformation-guided production of quinalizarin as an antibacterial agent against Acinetobacter baumannii.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The search for antibacterial agents remains a global priority, particularly against multidrug-resistant pathogens. In this study, microbial transformation of 1,8-dihydroxyanthraquinone (chrysazin) was performed to obtain derivatives with enhanced antibacterial activity. Biotransformation using Absidia corymbifera AUMC 7104 and Beauveria bassiana AUMC 5133 yielded two metabolites: 1,2,5,8-tetrahydroxyanthraquinone (1, quinalizarin) and 1,8-dihydroxy-3-methyl-anthraquinone (2, chrysophanol), respectively. Their structures were elucidated by HRESIMS, 1D/2D NMR analyses. To the best of our knowledge, this is the first report of quinalizarin production through microbial biotransformation. The antibacterial activities of both derivatives (1 and 2), along with their parent compound, were evaluated against multidrug-resistant Acinetobacter baumannii through in vitro assays. Compound 1 exhibited the least MIC values of 512-1024 µg/mL against A. baumannii isolates and was selected for further in vivo and in silico studies. In the murine infection model, the compound 1-treated group (group IV) exhibited a significant reduction (p < 0.05) in bacterial burden compared to the positive control group (group II). Immunohistochemical analysis of kidney, liver, and spleen tissues revealed modulation of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α, indicating anti-inflammatory properties alongside antibacterial activity. Molecular docking suggests a potential multi-target mechanism for compound 1, with favorable interactions with five critical bacterial proteins: MetRS, MurB, LptG/F, DXR, and MacB efflux transporter. These findings highlight quinalizarin as a potential lead compound for further antibacterial development. KEY POINTS: • Fungal biotransformation of chrysazin yielded the antibacterial agent quinalizarin. • Quinalizarin revealed in vitro and in vivo actions against Acinetobacter baumannii. • Docking studies suggested favorable interactions with multiple bacterial targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.